The Economics of Reproducibility in Preclinical Research
作者： Leonard P. Freedman , Iain M. Cockburn , Timothy S. Simcoe
DOI: 10.1371/JOURNAL.PBIO.1002165
关键词:
摘要: Low reproducibility rates within life science research undermine cumulative knowledge production and contribute to both delays costs of therapeutic drug development. An analysis past studies indicates that the (total) prevalence irreproducible preclinical exceeds 50%, resulting in approximately US$28,000,000,000 (US$28B)/year spent on is not reproducible—in United States alone. We outline a framework for solutions plan long-term improvements will help accelerate discovery life-saving therapies cures.
core.ac.uk
paperity.org参考文章(33)
Joseph Farrell, Timothy Simcoe, Four Paths to Compatibility ,(2012) , 10.1093/OXFORDHB/9780195397840.013.0002
Charles F. Manski, Partial Identification of Probability Distributions ,(2003)
Stavros C Manolagas, Henry M Kronenberg, Reproducibility of results in preclinical studies: a perspective from the bone field. Journal of Bone and Mineral Research. ,vol. 29, pp. 2131- 2140 ,(2014) , 10.1002/JBMR.2293
David Baker, Katie Lidster, Ana Sottomayor, Sandra Amor, Two years later: journals are not yet enforcing the ARRIVE guidelines on reporting standards for pre-clinical animal studies. PLOS Biology. ,vol. 12, ,(2014) , 10.1371/JOURNAL.PBIO.1001756
John P A Ioannidis, Sander Greenland, Mark A Hlatky, Muin J Khoury, Malcolm R Macleod, David Moher, Kenneth F Schulz, Robert Tibshirani, Increasing value and reducing waste in research design, conduct, and analysis The Lancet. ,vol. 383, pp. 166- 175 ,(2014) , 10.1016/S0140-6736(13)62227-8
Jon R. Lorsch, Francis S. Collins, Jennifer Lippincott-Schwartz, Fixing problems with cell lines Science. ,vol. 346, pp. 1452- 1453 ,(2014) , 10.1126/SCIENCE.1259110
Lewis L. Chuang, Quoc C. Vuong, Heinrich H. Bülthoff, Learned Non-Rigid Object Motion is a View-Invariant Cue to Recognizing Novel Objects. Frontiers in Computational Neuroscience. ,vol. 6, pp. 1- 8 ,(2012) , 10.3389/FNCOM.2012.00026
C. Glenn Begley, Lee M. Ellis, Drug development: Raise standards for preclinical cancer research Nature. ,vol. 483, pp. 531- 533 ,(2012) , 10.1038/483531A
LP Freedman, MC Gibson, The impact of preclinical irreproducibility on drug development. Clinical Pharmacology & Therapeutics. ,vol. 97, pp. 16- 18 ,(2015) , 10.1002/CPT.9
Andrew M Stern, Arturo Casadevall, R Grant Steen, Ferric C Fang, Financial costs and personal consequences of research misconduct resulting in retracted publications eLife. ,vol. 3, ,(2014) , 10.7554/ELIFE.02956